1. Epigenetics
    Stem Cell/Wnt
    JAK/STAT Signaling
    Autophagy
  2. JAK
    Autophagy

Ruxolitinib (Synonyms: INCB018424)

Cat. No.: HY-50856 Purity: 99.83% ee.: 98.14%
Data Sheet SDS Handling Instructions

Ruxolitinib is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, and has > 130-fold selectivity for JAK1/2 versus JAK3.

For research use only. We do not sell to patients.
Ruxolitinib Chemical Structure

Ruxolitinib Chemical Structure

CAS No. : 941678-49-5

Size Price Stock Quantity
10 mM * 1 mL in DMSO $66 In-stock
5 mg $60 In-stock
10 mg $70 In-stock
50 mg $120 In-stock
100 mg $160 In-stock
200 mg $260 In-stock
500 mg $460 In-stock
1 g $660 In-stock
5 g   Get quote  
10 g   Get quote  

* Please select Quantity before adding items.

Customer Review

Other Forms of Ruxolitinib:

    Ruxolitinib purchased from MCE. Usage Cited in: J Biol Chem. 2015 Nov 27;290(48):29022-34.

    106 autonomous Ba/F3 cells stably transduced with ALL-associated JAK3 mutant V674A or double mutant L857P/Y100A are treated with increasing concentration of Ruxolitinib (0–2 μM). Two hours after treatment, the cells are lysed and subjected to Western blot analysis. Phosphorylation of STAT5, JAK3, and JAK1 is detected using specific anti-pY694 STAT5, anti-pY980/81 JAK3, and anti-pY1034/35 JAK1 antibodies. Membranes are reprobed with anti-STAT5, anti-JAK3, anti-JAK1, and anti-β-actin an
    • Biological Activity

    • Protocol

    • Technical Information

    • Purity & Documentation

    • References

    Description

    Ruxolitinib is the first potent, selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays, and has > 130-fold selectivity for JAK1/2 versus JAK3.

    IC50 & Target

    IC50: 3.3 nM (JAK1), 2.8 nM (JAK2)

    In Vitro

    Ruxolitinib potently and selectively inhibits JAK2V617F-mediated signaling and proliferation, markedly increases apoptosis in a dose dependent manner, and at 64 nM results in a doubling of cells with depolarized mitochondria in Ba/F3 cells. Ruxolitinib demonstrates remarkable potency against erythroid colony formation with IC50 of 67 nM, and inhibits proliferating of erythroid progenitors from normal donors and polycythemia vera patients with IC50 values of 407 nM and 223 nM, respectively[1].

    In Vivo

    Ruxolitinib (180 mg/kg, orally, twice a day) results in survive rate of greater than 90% by day 22 and markedly reduces splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects in a JAK2V617F-driven mouse model[1]. In the Ruxolitinib group, the primary end point is reached in 41.9% of patients, as compared with 0.7% in the placebo group in the double-blind trial of myelofibrosis. Ruxolitinib results in maintaining of reduction in spleen volume and improvement of 50% or more in the total symptom score[2]. Ruxolitinib (15 mg twice daily) treatment leads a total of 28% of the patients to have at least a 35% reduction in spleen volume at week 48 in patients with myelofibrosis, as compared with 0% in the group receiving the best available therapy. The mean palpable spleen length has decreased by 56% with Ruxolitinib but has increased by 4% with the best available therapy at week 48. Patients in the ruxolitinib group has an improvement in overall quality-of-life measures and a reduction in symptoms associated with myelofibrosis[3].

    Clinical Trial
    NCT Number Sponsor Condition Start Date Phase
    NCT02553330 Incyte Corporation Alopecia Areata October 2015 Phase 2
    NCT00778700 Incyte Corporation Plaque Psoriasis October 2008 Phase 2
    NCT00820950 Incyte Corporation Plaque Psoriasis May 2007 Phase 2
    NCT01348490 Incyte Corporation Primary Myelofibrosis|Post Essential Thrombocythemia-myelofibrosis|Post Polycythemia Vera-myelofibrosis June 2011 Phase 2
    NCT03099304 Incyte Corporation Vitiligo April 19, 2017 Phase 2
    NCT00674479 M.D. Anderson Cancer Center|Incyte Corporation Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplastic Syndrome|Chronic Myelogenous Leukemia May 12, 2008 Phase 2
    NCT03011892 Incyte Corporation Atopic Dermatitis December 2016 Phase 2
    NCT00617994 Incyte Corporation Plaque Psoriasis August 2007 Phase 2
    NCT00550043 Incyte Corporation Rheumatoid Arthritis October 2007 Phase 2
    NCT01644110 University of Ulm Primary Myelofibrosis|Secondary Myelofibrosis|PMF|SMF|Post-PV MF|Post-ET MF August 2013 Phase 1|Phase 2
    NCT00934544 Novartis Pharmaceuticals|Novartis Myelofibrosis July 2009 Phase 3
    NCT01895842 M.D. Anderson Cancer Center|Incyte Corporation Leukemia February 2014 Phase 1
    NCT01751425 M.D. Anderson Cancer Center|Incyte Corporation Leukemia July 2013 Phase 1|Phase 2
    NCT02784496 M.D. Anderson Cancer Center|Incyte Corporation Myelofibrosis September 29, 2016 Phase 2
    NCT03041636 M.D. Anderson Cancer Center|Incyte Corporation Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Other Diseases of Blood and Blood-Forming Organs|Chronic Lymphocytic Leukemia March 8, 2017 Phase 2
    NCT02912754 Sunnybrook Health Sciences Centre|Novartis Leukemia, Lymphocytic, Chronic, B-Cell March 2017 Phase 1|Phase 2
    NCT01790295 John Mascarenhas|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Incyte Corporation|Novartis|Icahn School of Medicine at Mount Sinai Primary Myelofibrosis|Post Polycythemia Vera Myelofibrosis|Post Essential Thrombocythemia Myelofibrosis February 2013 Phase 2
    NCT02257138 M.D. Anderson Cancer Center|Incyte Corporation Leukemia|Myeloproliferative Diseases February 2015 Phase 1|Phase 2
    NCT00638378 Incyte Corporation Metastatic Prostate Cancer February 2008 Phase 2
    NCT02493530 Vanderbilt-Ingram Cancer Center Myelofibrosis|Polycythemia Vera July 2015 Phase 1
    NCT01251965 M.D. Anderson Cancer Center|Incyte Corporation Leukemia December 2010 Phase 1|Phase 2
    NCT03123588 Incyte Corporation Essential Thrombocythemia April 20, 2017 Phase 2
    NCT01950780 Columbia University|Alopecia Areata Initiative - Gates Foundation|Locks of Love Alopecia Areata August 2013 Phase 2
    NCT02809976 Tufts Medical Center Vitiligo January 2016 Phase 2
    NCT01445769 Incyte Corporation Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis September 2011 Phase 2
    NCT01340651 Incyte Corporation Myelofibrosis March 2011 Phase 2
    NCT02041429 Dana-Farber Cancer Institute|Incyte Corporation Recurrent Breast Cancer|Metastatic Breast Cancer February 2014 Phase 1|Phase 2
    NCT02066532 Kevin Kalinsky|Incyte Corporation|National Cancer Institute (NCI)|Columbia University Metastatic Breast Cancer|Breast Carcinoma|HER-2 Positive Breast Cancer June 2014 Phase 1|Phase 2
    NCT02469974 Marina Kremyanskaya|Incyte Corporation|Icahn School of Medicine at Mount Sinai Myelofibrosis|MF May 2015
    NCT02593929 University of Pittsburgh Head and Neck Squamous Cell Carcinoma January 2017 Early Phase 1
    NCT02267278 M.D. Anderson Cancer Center|MEI Pharma, Inc. Myeloproliferative Diseases January 12, 2015 Phase 2
    NCT00726232 Incyte Corporation Polycythemia Vera|Essential Thrombocythemia July 2008 Phase 2
    NCT02953678 Incyte Corporation Graft-versus-host Disease November 2016 Phase 2
    NCT03147742 Incyte Corporation Graft-versus-host Disease (GVHD)
    NCT02928978 Julie Nangia|Incyte Corporation|Translational Breast Cancer Research Consortium|Baylor Breast Care Center Ductal Carcinoma In Situ|Atypical Lobular Hyperplasia|Atypical Ductal Hyperplasia|Lobular Carcinoma In Situ January 2017 Phase 2
    NCT01562873 Dana-Farber Cancer Institute Breast Cancer June 2012 Phase 2
    NCT02015208 Sunnybrook Health Sciences Centre|Novartis Chronic Lymphocytic Leukemia April 2014 Phase 1|Phase 2
    NCT02613598 University of Michigan Cancer Center Hodgkin's Lymphoma|Lymphoma, Non-Hodgkin January 2016 Phase 1
    NCT03112603 Incyte Corporation Graft-versus-host Disease June 23, 2017 Phase 3
    NCT00509899 Incyte Corporation Myelofibrosis|Polycythemia Vera|Thrombocytosis June 2007 Phase 1|Phase 2
    NCT00639002 Incyte Corporation Relapsed Multiple Myeloma|Refractory Multiple Myeloma|Multiple Myeloma March 2008 Phase 2
    NCT02091752 Novartis Pharmaceuticals|Novartis Primary Myelofibrosis September 2014 Phase 2
    NCT02723994 Incyte Corporation|Children's Oncology Group B-cell Acute Lymphoblastic Leukemia August 2016 Phase 2
    NCT01693601 John Mascarenhas|Icahn School of Medicine at Mount Sinai Myelofibrosis January 2013 Phase 1|Phase 2
    NCT01702064 H. Lee Moffitt Cancer Center and Research Institute|Incyte Corporation Chronic Phase Chronic Myeloid Leukemia February 21, 2013 Phase 1
    NCT02973711 University of Michigan Cancer Center Leukemia, Chronic Myeloid May 22, 2017 Phase 1|Phase 2
    NCT03069326 Memorial Sloan Kettering Cancer Center|Incyte Corporation|Celgene|M.D. Anderson Cancer Center Myelofibrosis February 27, 2017 Phase 2
    NCT02400463 University of Michigan Cancer Center Hemophagocytic Syndrome (HPS) September 2015 Early Phase 1
    NCT03110822 Oncotherapeutics|Incyte Corporation Multiple Myeloma February 6, 2017 Phase 1
    NCT01776723 H. Lee Moffitt Cancer Center and Research Institute|Incyte Corporation Myelomonocytic Leukemia February 20, 2013 Phase 1|Phase 2
    NCT02155465 Memorial Sloan Kettering Cancer Center|Incyte Corporation Lung Cancer June 2014 Phase 1|Phase 2
    NCT02966353 Novartis Pharmaceuticals|Novartis Primary Myelofibrosis|Post-Polycythemia Vera-Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis April 2, 2017 Phase 2
    NCT02131584 M.D. Anderson Cancer Center|Incyte Corporation Leukemia September 2, 2014 Phase 2
    NCT01431209 University of Nebraska|National Cancer Institute (NCI) Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma August 2011 Phase 2
    NCT02253277 Novartis Pharmaceuticals|Novartis Chronic Myeloid Leukemia February 18, 2015 Phase 1|Phase 2
    NCT03153982 University of California, San Francisco|Incyte Pharmaceuticals Head and Neck Squamous Cell Carcinoma September 29, 2017 Phase 2
    NCT01375140 M.D. Anderson Cancer Center|Incyte Corporation Myeloproliferative Diseases September 2011 Phase 2
    NCT02718300 Incyte Corporation Myelofibrosis June 2016 Phase 2
    NCT01317875 Incyte Corporation|Novartis Myelofibrosis March 2011 Phase 1
    NCT02292446 Novartis Pharmaceuticals|Novartis Polycythemia Vera November 23, 2014 Phase 3
    NCT03144687 Incyte Corporation Myelofibrosis July 2017 Phase 2
    NCT02955940 Incyte Corporation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell November 2016 Phase 2
    NCT02119676 Incyte Corporation Metastatic Colorectal Cancer March 2014 Phase 2
    NCT02038036 Novartis Pharmaceuticals|Novartis Polycythemia Vera March 25, 2014 Phase 3
    NCT02598297 Novartis Pharmaceuticals|Novartis Early Myelofibrosis With High Molecular Risk Mutations February 3, 2016 Phase 3
    NCT01712659 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) T Cell Leukemia, Adult|Leukemia, Adult T-Cell|T Cell Leukemia, HTLV I Associated October 3, 2012 Phase 2
    NCT02876302 Dana-Farber Cancer Institute|Incyte Corporation Inflammatory Breast Cancer (IBC) April 26, 2017 Phase 2
    NCT02087059 Novartis Pharmaceuticals|Novartis Primary Myelofibrosis (MF) April 2014 Phase 3
    NCT02092324 OHSU Knight Cancer Institute|National Cancer Institute (NCI) Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative|Chronic Neutrophilic Leukemia May 2014 Phase 2
    NCT01730755 Washington University School of Medicine|Incyte Corporation Erythrocytosis, Familial, 2
    NCT02120417 Incyte Corporation Advanced or Metastatic HER2-negative Breast Cancer May 2014 Phase 2
    NCT02076191 John Mascarenhas|Myeloproliferative Disorders-Research Consortium|National Cancer Institute (NCI)|Incyte Corporation|Icahn School of Medicine at Mount Sinai Myeloproliferative Neoplasms February 2014 Phase 1|Phase 2
    NCT00952289 Incyte Corporation Myelofibrosis August 2009 Phase 3
    NCT01433445 Novartis Pharmaceuticals|Novartis Idiopathic Myelofibrosis|Post Essential Thrombocythemia Myelofibrosis|Post Polycythemia-Vera Myelofibrosis November 1, 2011 Phase 1
    NCT02117479 Incyte Corporation Metastatic Pancreatic Adenocarcinoma March 2014 Phase 3
    NCT02997280 St. Petersburg State Pavlov Medical University|Ministry of Health, Russian Federation Graft Vs Host Disease August 2016 Phase 2
    NCT02119663 Incyte Corporation Metastatic Pancreatic Adenocarcinoma That is Recurrent June 2014 Phase 3
    NCT02475655 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections February 2016 Phase 2
    NCT02420717 M.D. Anderson Cancer Center|Incyte Corporation Leukemia July 2015 Phase 2
    NCT02974647 Memorial Sloan Kettering Cancer Center|Cornell University|Dana-Farber Cancer Institute Lymphoma November 2016 Phase 2
    NCT02913261 Novartis Pharmaceuticals|Novartis Corticosteroid Refractory Acute Graft vs Host Disease March 10, 2017 Phase 3
    NCT02436135 Gilead Sciences Myelofibrosis June 5, 2015 Phase 1
    NCT02917096 City of Hope Medical Center|National Cancer Institute (NCI) Primary Myelofibrosis|Secondary Myelofibrosis October 5, 2016
    NCT01965119 Samsung Medical Center Relapsed or Refractory Hodgkin Lymphoma|Primary Mediastinal Large B-cell Lymphoma November 2013 Phase 2
    NCT02119650 Incyte Corporation Carcinoma, Non-Small-Cell Lung February 2014 Phase 2
    NCT02072057 Kantonsspital Aarau|Clinical Trial Unit, University Hospital Basel, Switzerland|University Hospital, Basel, Switzerland|Novartis Cancer Cachexia April 2014 Phase 2
    NCT02494882 Memorial Sloan Kettering Cancer Center|Incyte Pharmaceuticals|Novartis Pharmaceuticals Acute Lymphoblastic Leukemia June 29, 2015 Phase 1
    NCT01969838 Gilead Sciences Primary Myelofibrosis|Post-Polycythemia Vera Myelofibrosis|Post-Essential Thrombocythemia Myelofibrosis December 6, 2013 Phase 3
    NCT01822756 Incyte Corporation Metastatic Cancer|Metastatic Pancreatic Cancer April 2013 Phase 1
    NCT01732445 Mayo Clinic|National Cancer Institute (NCI) Anemia|Primary Myelofibrosis|Secondary Myelofibrosis April 2013 Phase 2
    NCT02528877 City of Hope Medical Center|National Cancer Institute (NCI) Acute Myeloid Leukemia in Remission|Primary Myelofibrosis|Primary Myelofibrosis, Prefibrotic Stage|Secondary Acute Myeloid Leukemia|Secondary Myelofibrosis November 2015 Phase 1
    NCT01594216 Abramson Cancer Center of the University of Pennsylvania Estrogen-receptor Positive Invasive Metastatic Breast Cancer April 2012 Phase 2
    NCT01914484 University Health Network, Toronto|Novartis Chronic Phase Chronic Myeloid Leukemia|Accelerated Phase Chronic Myeloid Leukemia|Blastic Phase Chronic Myeloid Leukemia|Philadelphia Positive Acute Lymphoblastic Leukemia|Resistant to Tyrosine Kinase Inhibitor Therapy August 2013 Phase 1|Phase 2
    NCT01423604 Incyte Corporation Metastatic Pancreatic Adenocarcinoma July 2011 Phase 2
    NCT01632904 Incyte Corporation Polycythemia Vera June 2012 Phase 3
    NCT02713386 NRG Oncology|National Cancer Institute (NCI) Fallopian Tube Clear Cell Adenocarcinoma|Fallopian Tube Endometrioid Adenocarcinoma|Fallopian Tube Serous Neoplasm|High Grade Ovarian Serous Adenocarcinoma|Ovarian Clear Cell Adenocarcinoma|Ovarian Endometrioid Adenocarcinoma|Primary Peritoneal Serous Adenocarcinoma|Stage III Fallopian Tube Cancer|Stage III Ovarian Cancer|Stage III Primary Peritoneal Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB May 2016 Phase 1|Phase 2
    NCT02145637 Yonsei University NSCLC July 2014 Phase 1
    NCT03012230 Mayo Clinic|National Cancer Institute (NCI) Breast Carcinoma Metastatic in the Bone|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Recurrent Breast Carcinoma|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma May 2017 Phase 1
    NCT02806375 St. Petersburg State Pavlov Medical University Primary Myelofibrosis|Myeloproliferative Disorders January 2016 Phase 1|Phase 2
    NCT01787487 M.D. Anderson Cancer Center|Incyte Corporation Leukemia March 2013 Phase 2
    NCT02593760 Hoffmann-La Roche Myelofibrosis January 2016 Phase 1|Phase 2
    NCT02049450 Novartis Pharmaceuticals|Novartis Thalassemia Major May 28, 2014 Phase 2
    NCT02386800 Novartis Pharmaceuticals|Novartis Splenomegaly March 7, 2015 Phase 4
    NCT02164500 University of Cologne Recurrent Classical Hodgkin Lymphoma October 2015 Phase 2
    NCT02370706 Novartis Pharmaceuticals|Novartis Myelofibrosis May 21, 2015 Phase 1
    NCT01243944 Incyte Corporation|Novartis Pharmaceuticals Polycythemia Vera October 2010 Phase 3
    NCT01164163 Children's Oncology Group|National Cancer Institute (NCI) Chronic Myeloproliferative Disorders|Leukemia|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Neoplasms|Unspecified Childhood Solid Tumor, Protocol Specific September 2010 Phase 1
    NCT02962388 French Innovative Leukemia Organisation|Novartis Pharmaceuticals Essential Thrombocythemia January 2017 Phase 2|Phase 3
    NCT02577926 RWTH Aachen University|Novartis Polycythemia Vera (PV)|Essential Thrombocythemia (ET) October 2015 Phase 3
    NCT01877005 The Lymphoma Academic Research Organisation|Novartis Hodgkin's Lymphoma July 2013 Phase 2
    NCT01392443 Novartis Pharmaceuticals|Novartis Primary Myelofibrosis (MF)|Post-Polycythemia Vera (PV) MF|Post-Essential Thrombocythemia (ET) MF August 1, 2011 Phase 2
    NCT01369498 Gilead Sciences Myelofibrosis June 2011 Phase 2
    NCT03117751 St. Jude Children's Research Hospital|Bristol-Myers Squibb|Incyte Corporation|Shire Acute Lymphoblastic Leukemia|Acute Lymphoblastic Lymphoma March 29, 2017 Phase 2|Phase 3
    NCT02251821 Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|National Heart, Lung, and Blood Institute (NHLBI) Primary Myelofibrosis|Secondary Myelofibrosis October 2014 Phase 2
    NCT02587598 Incyte Corporation Advanced Cancer October 2015 Phase 1|Phase 2
    NCT02638428 Samsung Medical Center|Ministry of health & welfare, Republic of Korea Relapsed Pediatric Solid Tumor|Refractory Pediatric Solid Tumor|Relapsed Pediatric AML|Refractory Pediatric AML December 2015 Phase 2
    View MoreCollapse
    References
    Preparing Stock Solutions
    Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
    1 mM 3.2640 mL 16.3201 mL 32.6403 mL
    5 mM 0.6528 mL 3.2640 mL 6.5281 mL
    10 mM 0.3264 mL 1.6320 mL 3.2640 mL
    Kinase Assay
    [1]

    Recombinant proteins are expressed using Sf21 cells and baculovirus vectors and purified with affinity chromatography. JAK kinase assays use a homogeneous time-resolved fluorescence assay with the peptide substrate (-EQEDEPEGDYFEWLE). Each enzyme reaction is carried out with Ruxolitinib or control, JAK enzyme, 500 nM peptide, adenosine triphosphate (ATP; 1mM), and 2% dimethyl sulfoxide (DMSO) for 1 hour. The 50% inhibitory concentration (IC50) is calculated as INCB018424 concentration required for inhibition of 50% of the fluorescent signal. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Assay
    [1]

    Ruxolitinib is dissolved in 0.2% final DMSO.

    Cells are seeded at 2×103/well of white bottom 96-well plates, treated with Ruxolitinib (INCB018424) from DMSO stocks (0.2% final DMSO concentration), and incubated for 48 hours at 37°C with 5% CO2. Viability is measured by cellular ATP determination using the Cell-Titer Glo luciferase reagent or viable cell counting. Values are transformed to percent inhibition relative to vehicle control, and IC50 curves are fitted according to nonlinear regression analysis of the data using PRISM GraphPad. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration
    [1]

    Ruxolitinib is suspended in 5% dimethyl acetamide, 0.5% methocellulose.

    Mice are fed standard rodent chow and provided with water ad libitum. Ba/F3-JAK2V617F cells (105 per mouse) are inoculated intravenously into 6- to 8-week-old female BALB/c mice. Survival is monitored daily, and moribund mice are humanely killed and considered deceased at time of death. Treatment with vehicle (5% dimethyl acetamide, 0.5% methocellulose) or Ruxolitinib (INCB018424) begin within 24 hours of cell inoculation, twice daily by oral gavage. Hematologic parameters are measured using a Bayer Advia120 analyzed, and statistical significance is determined using Dunnett testing. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    References
    Molecular Weight

    306.37

    Formula

    C₁₇H₁₈N₆

    CAS No.

    941678-49-5

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    DMSO: ≥ 36 mg/mL; H2O: < 0.1 mg/mL

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Purity: 99.83% ee.: 98.14%

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Ruxolitinib
    Cat. No.:
    HY-50856
    Quantity: